

CHICAGO

to the premier meeting in rheumatology



2011 ACR/ARHP

CALL FOR ABSTRACTS GUIDELINES

 **Abstract Submission Deadline: Tuesday, June 28, 2011, Noon Eastern Time**

GO! PRESENT AT THE ACR/ARHP ANNUAL SCIENTIFIC MEETING

The 2011 ACR/ARHP Annual Scientific Meeting is a forum for physicians and health professionals to receive the most relevant and latest developments in rheumatology. In addition to the presentation of abstracts, speakers selected by the ACR/ARHP Annual Meeting Planning Committees will provide clinical and basic science information in various formats. These include didactic lectures, debates, and interactive sessions (workshops, poster tours and meet the professor sessions).

Each year, the annual meeting draws thousands of abstracts submitted by rheumatologists and health professionals from around the world. We invite you to submit an abstract and take advantage of this opportunity to share your latest work with your colleagues.

WE LOOK FORWARD TO SEEING YOU IN CHICAGO

Chicago's great magic lies in its mix: sophisticated yet friendly, bustling city streets adjacent to long stretches of green parks, and sparkling blue Lake Michigan.

Chicago is more walkable than most global cities, and visitors of all ages enjoy the proximity of such attractions as Navy Pier, Millennium Park, Lincoln Park Zoo, Museum of Science and Industry, Art Institute of Chicago and other treasures.

Newcomers usually notice the architecture first. In this city where the skyscraper was born, city streets wind through urban canyons, shaped by the world's leading architects, and into diverse neighborhoods, each with its own fascinating flavor.

The city's explosive performance art scene delivers audience-thrilling theatre, music and dance in historic venues. And, of course, an endless assortment of restaurants, shopping and nightlife are all at your fingertips, ready to match every taste, budget and mood.

Remarkable shopping opportunities in Chicago's renowned department stores, upscale and trendy neighborhood boutiques, galleries, and specialty shops will satisfy your quest for a special memento or all-out retail therapy. For more information on Chicago attractions, shopping, entertainment and dining options, go to www.choosechicago.com.

All this and more make Chicago an outstanding choice for the 2011 ACR/ARHP Annual Scientific Meeting.

We look forward to seeing you there!

Chicago's great magic lies in its mix: sophisticated yet friendly, bustling city streets adjacent to long stretches of green parks, and sparkling blue Lake Michigan.

REGISTRATION & HOTEL ACCOMMODATION

Submitting an abstract or acceptance of an abstract does not register you or ensure hotel accommodations for the meeting; therefore, all attendees are required to register and pay the appropriate registration fees and arrange hotel accommodations.

Abstract presentation dates will be finalized in August, so authors should plan to attend the entire meeting. Registration and housing will open for members on Wednesday, June 8 and on Wednesday June 22, for non-members. For more information about registration and housing, please visit www.rheumatology.org/annual.

ABSTRACT SUBMISSION

This is your complete guide for submitting an abstract to the 2011 ACR/ARHP Annual Scientific Meeting. It is recommended that you read this guide prior to beginning the submission process as general guidelines and rules apply to all abstract submissions and specific criteria are outlined within each section.



The following is a summary of what's new for 2011 abstract submissions:

- A complimentary poster hanging service will be offered to all poster presenters.
- Acronyms will no longer be published in abstract titles. Acronyms may be included in the body of the abstract and in the author block as appropriate.
- If your research involved human subjects, you will be asked to attest that you received IRB approval.
- Poster hall will open at 8:30 AM each day to ensure that posters are hung 30 minutes prior to the start of the poster session.

Please read this entire guide prior to beginning the submission process to review the guidelines and rules that apply to abstract submissions.







TABLE OF CONTENTS



Eligibility	Page 4
Submitting an Abstract	Page 4
ACR Call for Abstracts	Page 5
Basic Research & Clinical Research Conferences Abstracts	Page 5
ARHP Call for Abstracts	Page 6
Students, Residents and Fellows-in-Training	Page 6
Abstract Disclosure Statement	Page 6
Abstract Review and Notification	Page 7
Presentation Format	Page 7
Permissions	Page 8
Publication	Page 9
Revisions	Page 9
Withdrawals	Page 9
Presenting Author Responsibilities	Page 10
Embargo Policy	Page 10
2011 ACR and ARHP Abstract Categories	Page 11
ACR Late-breaking Abstracts	Page 13



We look forward to seeing you there!


ELIGIBILITY

1. Abstracts describing original basic science and clinical work related to the broad area of rheumatic diseases may be submitted.
2. An abstract is ineligible for consideration if it reports work that has been accepted prior to the ACR/ARHP submission deadline of June 28, 2011, for publication as a manuscript.
3. The same study should not be submitted as multiple abstracts. Abstracts that appear as more than one version of a single study will be rejected.
4. By submitting your abstract, you agree to present the abstract if it is selected for presentation during an oral or poster abstract presentation.
5. Case reports submitted to the ACR or ARHP program are not considered appropriate and will not be reviewed.
6. If the abstract **reports** results of a clinical trial not yet approved by a regulatory agency, you will be required to identify the trial phase.
7. Abstracts submitted for the late-breaking category cannot be submitted to another category.
8. Abstracts submitted for the ARHP program may not be dually submitted to the ACR program.
9. You do not have to be a member of the ACR or ARHP to submit an abstract.
10. Any work with human or animal subjects reported in submitted abstracts must comply with the guiding principles for experimental procedures found in the Declaration of Helsinki of the World Medical Association.

SUBMITTING AN ABSTRACT

Go to www.rheumatology.org/annual or [click here](#) to get started. The 2011 ACR/ARHP abstract categories are listed on page 11.

For technical assistance regarding the abstract submission site, contact The Conference Exchange technical support at 401-334-0220 or via email at acr@confex.com between 8:30 AM and 6:00 PM, ET, Monday through Friday. For general inquiries regarding abstract submission, visit www.rheumatology.org/annual or call 404-633-3777.



Abstract Format

The abstract limit is 2,750 characters, which excludes the title, names of authors/co-authors, authors' affiliations, spacing and disclosures. However, imported tables and graphics will decrease the character count by 250 characters from the total limit allowed. Abstracts exceeding the character limit will be considered "incomplete." Abstracts marked "incomplete" at the close of the submission deadline will be ineligible for consideration.

Title

Titles should be brief, clearly indicating the nature of the presentation. When entering the abstract title online, use mixed case (do not use all caps), and do not put a period at the end of the title. Enter the title in the "title" field only and do not enter the title in the body of the abstract.

Example: This is a Properly Formatted Abstract Title

Please refrain from using acronyms in your abstract titles as the ACR/ARHP will no longer publish acronyms that are listed in the titles of abstracts. Acronyms may remain in the body of the abstract and in the author list.

Authors

Do not list authors or commercial relationships in the body of the abstract. Please consult with your co-authors on how they would like their names to appear prior to the submission of the abstract. You may list no more than 25 individual authors for each abstract.

See the abstract disclosure statement section on page 6, for additional author identification instructions.

Content

Omit all names and geographical references in the body of the abstract. Organize content as follows:

- Background or Statement of Purpose
- Methods, materials and analytical procedure used
- Summary of the results in sufficient detail to support conclusion
- Conclusions reached (do not state "results will be discussed")



Each year, the annual meeting draws thousands of abstracts submitted by rheumatologists and health professionals from around the world.



Use of Product Names

The non-proprietary (generic/scientific) name can be used in your abstract. The proprietary drug name may appear once in parentheses in the title only. However, if a drug has not received FDA approval, only the non-proprietary name may be used in the title and abstract content. Failure to comply will result in disqualification of your submission.

Abbreviations

Use standard abbreviations. Place special or unusual abbreviations in parentheses after the first time the full word appears. Do not abbreviate compounds in the title of the abstract. Use numerals to indicate numbers, except when beginning sentences.

Tables and Graphics

Specific information regarding acceptable graphic files is included in the online submission program. Microsoft PowerPoint® files are not accepted.

ACR CALL FOR ABSTRACTS

The program for the ACR Annual Scientific Meeting includes content related to the clinical practice and teaching of rheumatology and the basic and translational science which contribute to the understanding of disease pathogenesis, the mechanisms and efficacy of therapeutics and the delivery of health care to patients with musculoskeletal and rheumatic disease.


SUBMISSION DEADLINE: June 28, 2011, Noon Eastern Time

SUBMITTING AN ABSTRACT

Go to www.rheumatology.org/annual or [click here](#) to get started. The 2011 ACR abstract categories are listed on page 11.

Abstract Processing Fee

A \$70 processing fee must accompany each abstract. The ACR accepts electronic payment only in the form of MasterCard, Visa and American Express. Abstract processing fees must be in U.S. funds and are non-refundable – no exceptions.



BASIC RESEARCH AND CLINICAL RESEARCH CONFERENCES ABSTRACTS

Young investigators may also submit an abstract that has been submitted to the ACR general program, to the Basic Research Conference or Clinical Research Conference for consideration. Young investigators will be required to check a box during the submission process to indicate if they want to have their abstract considered for inclusion in either conference. Acceptance to the ACR program is a prerequisite for consideration by the Basic Research Conference or Clinical Research Conference, and acceptance to either of these conferences does not remove the abstract from the ACR general program.

SUBMISSION DEADLINE: June 28, 2011, Noon Eastern Time

Eligibility

- Only investigators with less than six years of experience are eligible to submit an abstract to the Basic Research Conference or Clinical Research Conference.
- Abstracts must also be submitted to the ACR general program.

ACR Basic Research Conference Criteria

Abstracts should be related to bone biology in inflammatory and rheumatic disorders, including pathologic bone remodeling in osteoarthritis and inflammatory rheumatic diseases, the role of the immune system in regulating bone cell differentiation and activity, mechanisms underlying deregulated bone remodeling in Paget's disease of bone, and genetic and pediatric disorders of bone remodeling. Abstracts related to therapeutic interventions aimed at modulating bone turnover will also be considered.

ACR Clinical Research Conference Criteria

Abstracts should be those related broadly to the area of comparative effectiveness research, or to the development of evidence-based treatments through participation in registries, as relates to the practice of rheumatology.

Abstract Processing Fee

There is no additional fee to have your abstract considered for either conference.

Format

Abstracts may be selected for oral or poster presentation, and the presenting authors should be prepared to present in either format. Accepted abstract presentations will be held during the pre-conference courses on Friday, November 4 or Saturday, November 5.

SUBMISSION DEADLINE: June 28, 2011, Noon Eastern Time





ARHP CALL FOR ABSTRACTS

The ARHP program is planned to reflect the needs and interest of healthcare professionals who share an interest in rheumatology-related issues by providing a forum to address issues of professional significance with a multidisciplinary audience.

SUBMISSION DEADLINE: June 28, 2011, Noon Eastern Time

SUBMITTING AN ABSTRACT

Go to www.rheumatology.org/annual or [click here](#) to get started. The 2011 ARHP abstract categories are listed on page 12.

Abstract Processing Fee

A \$40 processing fee must accompany each abstract. The ARHP accepts electronic payment only in the form of MasterCard, Visa and American Express. Abstract processing fees must be in U.S. funds and are non-refundable – no exceptions.

FOR STUDENTS, RESIDENTS AND FELLOWS-IN-TRAINING

Submission by Students, Residents and Fellows-in-Training as Presenting Authors

The ACR encourages the submission of abstracts by presenting authors who are pre-doctoral and post-doctoral students, residents, medical students or fellows-in-training. Please check the box on the submission site to indicate your training status.

REF Abstract Award

The ACR Research and Education Foundation offers award opportunities for medical students, residents, and pediatric rheumatology fellows who submit an abstract for the 2011 ACR/ARHP Annual Scientific Meeting by the June 28 submission deadline. Award recipients will receive a cash award plus reimbursement of travel expenses to attend the meeting. Acceptance of an abstract does not automatically enroll or guarantee receipt of the REF Abstract Award.

Visit www.rheumatology.org/annual or call (404) 633-3777, ext. 318 for complete details.

ABSTRACT DISCLOSURE STATEMENT

All authors must disclose any relevant financial relationship(s) at the time of abstract submission. Examples include, but are not limited to:

None: has no relevant financial relationship to disclose

1. Stock options or bond holdings in a for-profit corporation or self-directed pension plan
2. Research grants
3. Employment (full or part-time)
4. Ownership or partnership
5. Consulting fees or other remuneration
6. Non-remunerative positions of influence such as officer, board member, trustee or public spokesperson
7. Receipt of royalties
8. Speakers' bureau
9. Other

Disclosures collected at the time of submission will be published in the scientific program, abstract supplement and on the ACR website. Abstracts will not be accepted without proper completion of the conflict of interest/disclosure section on the abstract submission form. Failure to disclose correctly may lead to corrective action as deemed appropriate by the ACR or ARHP leadership. The abstract review process is blinded; therefore, the disclosure information you provide will not influence the review of your abstract.

Involvement of Individuals Not Listed as Authors

Names of all individuals who had a substantial role in the study or abstract preparation who are not included in the list of authors must be disclosed. For each individual, please describe the activity or activities, the reason the individual is not listed as an author, and the manner in which the individual's participation is being disclosed to the learner, e.g., studies design, acquisition of data, analysis and interpretation of data, abstract preparation, statistical analysis or other. These disclosures will be published in electronic version only on the ACR website.



The ACR Research and Education Foundation offers award opportunities for medical students, residents, and pediatric rheumatology fellows who submit an abstract for the 2011 ACR/ARHP Annual Scientific Meeting by the June 28 submission deadline.



Study Sponsor Statements

For abstracts about studies that were funded by a pharmaceutical or biotech company or other commercial enterprise, a “Role of the Study Sponsor” statement must be included (use plural “Sponsors” if more than one sponsor is listed). This statement describes for the learner the part played by the commercial entity in the conduct and reporting of the study.

Note: This applies only to commercial enterprises (e.g., pharmaceutical or biotech companies; device manufacturing companies). It does not apply to government entities such as the NIH or its equivalent funding agencies in other countries or to public or private foundations. This statement will be published in electronic version only on the ACR website.

Institutional Review Board Affirmation

An Institutional Review Board is charged with protecting the rights and welfare of people involved in research. If your research involved human subjects, you will be required to check a box during the submission process to attest that you have received IRB approval.

ABSTRACT REVIEW AND NOTIFICATION

After the submission deadline, completed abstracts will be peer-reviewed. “Incomplete” abstracts will not be considered. To ensure the integrity of the review process, revisions to abstracts will not be accepted after the submission deadline – no exceptions.

Abstracts will be peer-reviewed by a subsection of the ACR Abstract Selection Committee or the ARHP Program Committee, according to subject categories. All reviewers will be required to sign a confidentiality agreement.

- All abstracts will be reviewed without knowledge of the author(s), institution(s) or disclosure information.
- Accepted abstracts will be selected as either a short oral presentation or a poster presentation.
- **The presenting author is the only author who will receive notification and is the point of contact for all co-authors.** Presenting authors will be notified in August. The late-breaking presenting authors will be notified in October.

PRESENTATION FORMAT

If your abstract can only be presented as a poster, please check the appropriate box during the submission process. As English is

the designated language for the meeting, the presenting author is required to speak English when presenting.

Oral Abstract Presentation

Oral presentations will be 15-minute podium presentations. The presenter will have 12 minutes for presentation and three minutes for discussion.

Oral abstract presenters will be required to bring their presentation in an electronic format to the on-site Speaker Ready Room, where they will have the opportunity to review and/or revise presentations using computers in the room. All presentations will be uploaded to a central server and sent to the appropriate meeting room on a secured intranet circuit prior to the start of the session. All slides will be checked for adherence to ACCME policies by ACR staff prior to uploading the presentation.

Poster Abstract Presentation

Poster presentations facilitate one-on-one interaction between the presenters and attendees. Posters are grouped by topic and displayed in the poster hall area from Sunday, November 6 - Tuesday, November 8. One poster session will be held each day. Presenting authors must be available at their poster from 9:00 – 11:00 AM to answer questions from meeting attendees as well as poster tour participants.

In order to ensure a positive experience for both attendees and poster presenters, it is important to make sure that all posters are properly mounted and presenters are present from 9:00 – 11:00 AM for poster presentations. Please note that the ACR will be monitoring posters during the presentation hours in an effort to make certain that the ACR is meeting the educational needs and expectations of attendees.

Posters must be mounted and dismantled during the designated times as outlined in the abstract acceptance notification. Each poster board measures 44 inches (111.76 cm) high and 90 inches (228.6 cm) wide. Posters should not exceed these size specifications. The presenter must provide the presentation material for the poster board, including a copy of the abstract and all relevant disclosure information. Text and illustrations must be readable from distances of at least three feet. Use lightweight materials only; heavy articles are difficult to secure. Posters may be broken down into several smaller portions, but must not exceed the maximum size listed. Push pins to mount materials will be available on site. No audiovisual, projection or computer equipment requiring electrical power will be permitted in the poster session area.



Go to www.rheumatology.org/annual or [click here](#) to get started.



Poster Printing Service

Eliminate the hassle of traveling with your poster! ACR is partnering with Mira Digital Publishing, a leading purveyor of high-quality scientific poster presentations, to offer poster printing service. Mira Digital Publishing specialists will handle everything, from layout to printing and shipping directly to Chicago. You'll have multiple poster templates to choose from. *It's that easy!* For more information on poster printing services, visit www.rheumatology.org/annual.



Poster Hanging Service

Poster drop off/pick up and hanging service will be implemented this year. Drop off your poster by 5:00 PM the day prior to your poster session and one of the ACR's friendly staff will hang your poster for you. We will also remove your poster and store it for you until 6:30 PM on Tuesday, November 8. This complimentary service will be available to all poster presenters. Posters not collected by 6:30 PM on Tuesday, November 8 will be discarded.

Guided Poster Tours

Guided poster tours, led by experts in the field, will guide small groups of attendees during the poster presentation times to highlight novel or recent developments. Selected posters from various abstract categories will be included in the tours.

ACCME Standard and ACR Policy Regarding Third-Party Bias

In accordance to ACCME requirements and ACR policy, abstracts selected for oral or poster presentation must be free of bias. Do not reference any company/product brand names during your presentation. However, institution logos (e.g., non company/product logos such as universities, non-profit associations and government agencies) are allowed in the body of your presentation. ACR requires that educational materials that are part of a CME activity, such as slides,

abstracts and handouts, do not contain any advertising, trade names or a product-group message. Disclosure must never include the use of a trade name or a product-group message. For oral presentations, disclosure must be listed on the second slide of each presentation. For poster presentations, disclosure must be listed once at the bottom of the poster.



PERMISSIONS

Media Coverage

Media exposure benefits the ACR in publicizing its meetings and brings awareness to current healthcare issues and treatment options. Members of the media may be in attendance during your session. In addition to articles about your presentation, media may also take photographs during the meeting. By the rights and privileges of freedom of the press, the ACR does not have the authority to obtain articles prior to publication for editing. However, in the instance of gross negligence by a member of the media of factual information concerning your presentation or your credentials, the ACR will assist in contacting the media to make them aware of the error.

Recording

As a part of the abstract submission process, primary authors will be requested to allow the College to use their presentation in connection with its education resources, including *SessionSelect*. If selected as an oral abstract presentation, your presentation may be selected to be audio and/or video recorded and distributed by the ACR in furtherance of its educational purposes. All royalties will be paid to the ACR and all claims for royalties in conjunction with the distribution of your presentation are waived. This agreement and the Copyright License do not preclude publication of your presentation by you at any time, in any form.



ACR is partnering with Mira Digital Publishing, a leading purveyor of high-quality scientific poster presentations, to offer poster printing service.



PUBLICATION

Accepted abstracts will be published in a supplement of the October issue of *Arthritis & Rheumatism*, an official journal of the American College of Rheumatology. Accepted late-breaking abstracts will be published in the December issue of *Arthritis & Rheumatism*. All accepted abstracts will be available on the ACR website in September.

REVISIONS

Proofread abstracts carefully to avoid errors prior to submission. Your abstract, if selected, will be published in print and electronic versions exactly as submitted. You may return to the online submission site to revise your abstract until Noon Eastern Time on June 28, 2011. After this date/time, the submission site will close and changes will not be made. Should a submission contain errors or the omission of contributing author names after the deadline, the abstracts may be withdrawn.

WITHDRAWALS

After June 28, presenting authors may submit a request to have an abstract withdrawn. All requests must be submitted via e-mail to withdrawn@rheumatology.org. Requests must include the abstract number, the title of the abstract and the presenting author's name. The removal of the abstract from the October supplement of *Arthritis & Rheumatism* cannot be guaranteed if the request is received after September 23, 2011.



Guided poster tours, led by experts in the field, will guide small groups of attendees during the poster presentation times to highlight novel or recent developments.





PRESENTING AUTHOR RESPONSIBILITIES

At the time of submission, the person submitting the abstract must identify who will be designated as the presenting author. The presenter is required to speak English when presenting, as this is the designated language for the meeting.

The presenting author will be the sole point of contact for information regarding the submission and is responsible for the following:

- Ensuring each co-author is aware of the content of the abstract and supports its data. Failure to receive approval from each co-author will result in the abstract being disqualified.
- Ensuring each co-author is aware of the disclosure requirements.
- Adhering to the Abstract Disclosure Statement and obtaining disclosure information from all co-authors (see page 6).
- Forwarding abstract acceptance/rejection notification and ACCME and ACR polices to each co-author.
- Presenting the abstract or arranging for a co-author to present the abstract if it is selected for presentation during an oral and/or poster session.

Note: If you are the presenting author and you have accepted an invitation to participate as an invited speaker or moderator and a schedule conflict is identified, you will be required to appoint a co-author to present the abstract. Only co-authors listed on the accepted abstract may present the abstract – this includes poster presentation. Invited speaker or moderator schedules cannot be changed to accommodate abstract oral or poster presentations.

- Notifying each co-author of any changes to the program, as corresponded by the ACR or ARHP, in a timely manner.

The presenting author must comply with these responsibilities or be subject to corrective action as deemed appropriate by the ACR or ARHP leadership.

Presenting Author Affirmations

The ACR does not condone presentations given by an invited presenter who has not been intimately involved in the development of the data and who cannot meet the criteria for authorship. To be eligible to present, at the time of submission, the presenting authors will be required to confirm agreement with the following affirmation statements:

- I confirm I had full access to all of the data in the study, and take responsibility for the integrity of the data and the accuracy of the data analysis and approved the data for presentation.
- I confirm I made significant contributions to the study design, analysis or interpretation of results.


EMBARGO POLICY

Accepted abstracts are made available to the public on the ACR website in advance of the meeting and are published in a special supplement of *Arthritis & Rheumatism*. Information contained in those abstracts may not be released until the abstracts appear on the ACR website. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website.

However, the ACR continues to require that information that goes beyond that contained in the abstract, e.g., discussion of the abstract done as part of a scientific presentation or presentation of additional new information that will be available at the time of the meeting, is under embargo until 5:00 PM Eastern Time on Saturday, November 5. Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy.

At the time of submission, the person submitting the abstract must identify who will be designated as the presenting author.





2011 ACR AND ARHP ABSTRACT CATEGORIES

ACR CATEGORIES



1. **Cytokines, Mediators, and Gene Regulation:** cytokines, chemokines, and their receptors; downstream signaling effects and biologic pathways.
2. **Cell-cell Adhesion, Cell Trafficking and Angiogenesis:** cell-cell recognition and adhesion molecules, cell-matrix interactions, matrix characteristics and properties, and lymphoid organogenesis.
3. **Innate Immunity and Rheumatic Disease:** dendritic cells, antigen presentation, phagocytes, pattern recognition receptors and their ligands, NK cells, complement, and Fc receptors.
4. **B cell Biology and Targets in Autoimmune Disease:** B-lymphocyte differentiation, B-cell subsets, plasma cells, autoantigens, autoreactive B-cells, and tissue injury.
5. **T cell Biology and Targets in Autoimmune Disease:** T-lymphocyte antigens and subpopulations, cognate interactions, T-lymphocyte activation and proliferation.
6. **Biology and Pathology of Bone and Joint:** joint biology and biochemistry, cartilage and chondrocyte biology, basic studies of osteoarthritis, bone structure and function, bone mineral and matrix, osteoblasts and osteoclasts.
7. **Osteoarthritis – Clinical Aspects:** patient-oriented studies of osteoarthritis, including treatment, diagnosis, outcomes.
8. **Osteoporosis and Metabolic Bone Disease:** Clinical Aspects and Pathogenesis: patient-oriented studies of bone structure and integrity and its change in various disease states.
9. **Fibromyalgia and Soft Tissue Disorders:** regional pain syndromes, local diseases of muscle, ligament and tendon, fibromyalgia, miscellaneous rheumatic syndromes.
10. **Orthopedics, Low Back Pain, and Rehabilitation:** orthopedic conditions and interventions, physical medicine techniques and outcomes, sports medicine.
11. **Pediatric Rheumatology – Clinical and Therapeutic Aspects:** clinical aspects and treatment of inflammatory and non-inflammatory pediatric conditions.
12. **Pediatric Rheumatology – Pathogenesis and Genetics:** pathological, genetic, and other laboratory-based aspects of pediatric rheumatology conditions.
13. **Infection-related Rheumatic Disease:** musculoskeletal manifestations of infectious disease, reactive arthritis, infectious arthritis, and molecular pathogenesis.
14. **Metabolic and Crystal Arthropathies:** crystal-induced arthritis, metabolic conditions including endocrine abnormalities.
15. **Muscle Biology, Myositis and Myopathies:** muscle biology, inflammatory and non-inflammatory muscle disease.
16. **Imaging of Rheumatic Diseases:** radiology, nuclear medicine, MRI, ultrasound, thermography.
17. **RA – Clinical Aspects:** clinical aspects of rheumatoid arthritis.
18. **RA Treatment – Small Molecules, Biologics and Gene Therapy:** treatment of human rheumatoid arthritis including DMARDs, NSAIDs, glucocorticoids, new potential small molecules, biologics and gene therapy approaches. Human use only.
19. **RA - Human Etiology and Pathogenesis:** genetics, susceptibility loci, etiology and pathogenesis of human rheumatoid arthritis.
20. **RA - Animal Models:** animal models of inflammatory synovitis, mechanisms and treatment.
21. **Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics:** clinical aspects of these syndromes and of treatments.
22. **Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics:** cellular and molecular mechanisms, biomarkers.
23. **Sjögren's Syndrome:** pathophysiology, presentation and treatment of Sjögren's syndrome.
24. **Antiphospholipid Syndrome:** the pathophysiology, presentation and management of the antiphospholipid syndrome.
25. **SLE – Clinical Aspects and Treatment:** diagnosis, clinical manifestations, outcomes, and treatment, including new small molecules, biologics and gene therapy. Human lupus only.



Accepted abstracts are made available to the public on the ACR website in advance of the meeting and are published in a special supplement of Arthritis & Rheumatism.

26. **SLE – Human Etiology and Pathogenesis:** genetics, susceptibility loci, etiology and pathogenesis of human SLE.
 27. **SLE – Animal Models:** animal models, mechanisms and treatment.
 28. **Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment:** small molecule and biologic therapies of spondylarthropathies and psoriatic arthritis.
 29. **Spondylarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology:** etiology and pathogenesis of spondylarthropathies, including genetics and susceptibility loci.
 30. **Vasculitis:** genetics, etiology, pathogenesis, presentation and management of local and systemic vasculitis.
 31. **Epidemiology and Health Services Research:** descriptive and/or analytical studies of populations as well as economic analysis; decision making; quality of care and quality of life assessment.
 32. **Quality Measures and Innovations in Practice Management and Care Delivery:** quality measures and changes in practice management or delivery of health care affecting patients with arthritis, rheumatic or musculoskeletal disorders.
 33. **Genetics, Genomics and Proteomics:** techniques, strategies and observations related to disease susceptibility and expression; genetic disorders with rheumatic manifestations not included in other categories.
 34. **Education:** techniques, strategies and observations related to disease susceptibility and expression.
 35. **Miscellaneous Rheumatic and Inflammatory Diseases:** rheumatic manifestations and therapy of less common and even rare illnesses that are not included in other categories (e.g., RS3PE, reticulohistiocytosis, SAPHO).
- ARHP CATEGORIES**
36. **Clinical Practice/Patient Care:** care of patients, practice management, medication monitoring/adherence and behavioral aspects of care. Research presentations share scientific findings, controlled studies and other analysis of rheumatology related data.
 37. **Education/Community Programs:** patient education, professional education, community-based programs and public health programs. Research presentations share scientific findings, controlled studies and other analysis of rheumatology related data.
 38. **Epidemiology and Public Health:** descriptive and analytical studies of health status and health outcomes of populations and patient groups. Research presentations share scientific findings, controlled studies and other analysis of rheumatology related data.
 39. **Health Services Research:** health care systems and delivery economic evaluations and analysis. Research presentations share scientific findings, controlled studies and other analysis of rheumatology related data.
 40. **Pediatrics:** pediatric practice and patient care. Research presentations share scientific findings, controlled studies and other analysis of rheumatology related data.
 41. **Psychology/Social Sciences:** psychology, social work, social and behavioral factors affecting patients, families and providers. Research presentations share scientific findings, controlled studies and other analysis of rheumatology related data.
 42. **Rehabilitation Sciences:** physical therapy, occupational therapy, exercise programs and other rehabilitation services. Research presentations share scientific findings, controlled studies and other analysis of rheumatology related data.
 43. **Research Methodology:** questionnaire design, new assessment tools and methodology, new analytical techniques, and subject recruitment and retention. Research presentations share scientific findings, controlled studies and other analysis of rheumatology related data.

The late-breaking abstract category allows for the submission of truly late-breaking scientific research for which no preliminary data are available at the time of the June 28, 2011, abstract submission deadline.





ACR LATE-BREAKING ABSTRACTS

Eligibility

The late-breaking abstract category allows for the submission of truly late-breaking scientific research for which no preliminary data are available at the time of the June 28, 2011, abstract submission deadline. An abstract is ineligible for consideration if it reports work that has been accepted prior to the ACR late-breaking submission deadline of October 11, 2011, for publication as a [manuscript](#).

This category is not a mechanism to allow for updated data to be submitted later when preliminary data are available by the abstract submission deadline. Please note the following:

- The abstract must deal only with clinical research.
- Case reports are not considered appropriate and will not be reviewed.
- Abstracts should present data that is ground-breaking, innovative and has a high impact factor.

In order for an abstract to be considered for late-breaking presentation, the presenting author must:

- Explain in 50 words or less why the abstract is being submitted to the late-breaking category and why it is especially newsworthy and deserving of consideration. Stating the “results are just now available” is not a sufficient explanation.
- Indicate a primary research category, e.g., Clinical, Observational, Interventional, etc.
- Identify the trial phase, if the abstract reports results of a clinical trial not yet approved by a regulatory agency.

SUBMITTING AN ABSTRACT

Abstracts must be submitted online at www.rheumatology.org/annual.

The late-breaking abstract submission site will open on September 19.

SUBMISSION DEADLINE: October 11, 2011, Noon Eastern Time

Abstract Processing Fee

A \$130 processing fee must accompany each late-breaking abstract. The ACR accepts electronic payment only in the form of MasterCard, Visa and American Express. Abstract processing fees are non-refundable – no exceptions.

Format

Abstracts will be selected for oral or poster presentations and submitters should be prepared to present in either format.

Withdrawals

After October 11, presenting authors may submit a request to have an abstract withdrawn. All requests must be submitted via e-mail to withdrawn@rheumatology.org. Request must include the control number of the abstract, the title of the abstract and the presenting author’s name. The removal of the abstract from the December issue of *Arthritis & Rheumatism* cannot be guaranteed, if the request is received after October 28.

Late-breaking abstracts are also subject to the ACR’s Embargo Policy.



See you in Chicago!



CHICAGO

to the premier meeting in rheumatology



Chicago **ACR/ARHP 11**
Scientific Meeting

Pre-Conference Courses: November 4-5, 2011
Annual Scientific Sessions: November 5-9, 2011

WWW.RHEUMATOLOGY.ORG/ANNUAL